Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Houten R, Greenhalgh J, Mahon J, Nevitt S, Beale S, Boland A, Lambe T, Dundar Y, Kotas E, McEntee J. Houten R, et al. Pharmacoecon Open. 2021 Mar;5(1):13-22. doi: 10.1007/s41669-020-00206-x. Pharmacoecon Open. 2021. PMID: 32291725 Free PMC article. Review.
Informed consent failures: National Health Service Resolution data.
Ainsworth N, Hussain MI, Houten R, Martin AP, Toh S, Rao C, St John ER. Ainsworth N, et al. Among authors: houten r. Br J Surg. 2023 Jul 17;110(8):993-995. doi: 10.1093/bjs/znad131. Br J Surg. 2023. PMID: 37172194 No abstract available.
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C, Houten R, Boland A, Kaltenthaler E, Dickson R. Carroll C, et al. Among authors: houten r. Value Health. 2018 Mar;21(3):341-350. doi: 10.1016/j.jval.2017.09.006. Epub 2017 Oct 18. Value Health. 2018. PMID: 29566842 Free article.
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Stainthorpe A, et al. Among authors: houten r. Pharmacoecon Open. 2020 Dec;4(4):563-574. doi: 10.1007/s41669-020-00203-0. Pharmacoecon Open. 2020. PMID: 32207075 Free PMC article. Review.
140 results